

# **Revolutionizing Women's Sexual and Reproductive Health**

---

Piper Jaffray 31<sup>st</sup> Annual Healthcare Conference  
December 4, 2019

**Saundra Pelletier  
Chief Executive Officer**



# Forward-Looking Statements

---

This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "strategy," "objective," "designed," "suggest," "currently," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

- the outcome or success of Evofem's clinical trials
- Evofem's ability to obtain the necessary regulatory approvals for its product candidates, including approval from the U.S. Food and Drug Administration for the use of Amphora® as a contraceptive, and the timing of such approvals
- the rate and degree of market acceptance of Amphora®
- Evofem's ability to successfully commercialize Amphora® and its ability to develop sales and marketing capabilities
- Evofem's ability to maintain and protect its intellectual property
- Evofem's ability to raise additional capital when needed and to rely on existing cash reserves to fund its current development plans and operations
- Evofem's reliance on third party providers, such as third party manufacturers and clinical research organizations
- the absence of any adverse events or side effects relating to the use of Amphora®
- Evofem's ability to retain members of its management and other key personnel
- and other risk factors detailed in Evofem's filings from time to time with the U.S. Securities and Exchange Commission including, without limitation, the 10-K filed on March 1, 2019 and subsequent filings

The forward looking statements in this presentation represent Evofem's views only as of the date of this presentation, December 4, 2019, and Evofem expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evofem's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this presentation are qualified in their entirety by this cautionary statement.

# About Evofem Biosciences

## A Clinical-Stage Biopharmaceutical Company

committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health



## Amphora® for the Prevention of Pregnancy




Multipurpose Vaginal pH Regulator  
(MVP-R™)

- ✓ First-in-Class MOA
- ✓ Non-hormonal
- ✓ Female-controlled
- ✓ “On Demand”

# The Amphora Opportunity


Of the ~45M women at-risk for unintended pregnancy  
**17M segment out as potential Amphora adopters**




- Actively in search of new options
  - Moving away from hormones
  - Early adopters
- 
- Don't regularly use birth control or
  - Dissatisfied with current birth control

# Additional *Exploratory* Finding...

AMPOWER participants reported an almost **three fold increase** in sexual satisfaction



# AMPREVENCE: Top-line Phase 2b Results



Amphora was generally safe and well tolerated. Adverse events were similar across both arms (7.2% for Amphora and 7.5% for placebo).

## **Significant Key Milestones and Next Steps**

- ✓ **Resubmitted Amphora NDA for the prevention of pregnancy to the FDA**
  - Accelerating pre-commercial activities and launch preparations
- ✓ **Reported positive top-line results from the AMPREVENCE trial**
  - Will be requesting an end-of-Phase 2 meeting with the FDA
- ✓ **Conducting additional market research**
  - Results will enhance our understanding of the opportunity for Amphora for the prevention of chlamydia and gonorrhea





EYOFEM  
BIOSCIENCES®